
    
      This is an international, multicentre, randomised, double-blind, placebo-controlled study.

      Patients will be randomized 2:1 to receive either active and placebo Approximately 132
      participants will be screened, of which 105 will be enrolled Study participation will be up
      to a maximum duration of 19 weeks and will comprise a screening period (1 to 2 weeks) and a
      treatment period (16 weeks). A telephone follow-up call will be performed 1 week after the
      end of treatment
    
  